Alkermes ALKS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Aristada And Aristada Initio | $93.82M-3.5% | $97.22M-0.8% | $98.05M-3.2% | $101.3M+37.9% | $73.48M-24.0% | |
| LUMRYZ | $39.49M— | —— | —— | —— | —— | |
| LYBALVI | $92.36M-1.9% | $94.14M-4.2% | $98.25M+16.6% | $84.28M+20.4% | $70.02M-9.0% | |
| Vivitrol | $112.43M-9.4% | $124.13M+2.5% | $121.13M-0.4% | $121.66M+20.5% | $101M-24.7% | |
| Accrued Sales Discounts Allowances And Reserves by Product | ||||||
| Medicaid Rebate | $189.03M+1.6% | $186.07M-2.8% | $191.43M+1.3% | $189.02M-1.3% | $191.47M-5.2% | |
| Medicare Part D | $25.49M+0.5% | $25.37M+34.8% | $18.82M-21.3% | $23.91M+4.5% | $22.89M-15.0% | |
| Other | $39.62M+133% | $17M-31.4% | $24.78M+5.9% | $23.41M+16.6% | $20.08M-16.8% | |
| Product Discounts | $18.7M+0.1% | $18.69M+5.5% | $17.71M+5.2% | $16.83M+9.7% | $15.35M-20.7% | |
| Actual Credits Received Related To Duplicate Billings by Product | ||||||
| Aristada And Aristada Initio | $2.8M-79.4% | $13.6M+12.4% | $12.1M+68.1% | $7.2M— | —— | |
| LYBALVI | $500K— | —— | —— | —— | —— | |
| Vivitrol | $5.4M-79.8% | $26.7M+5.5% | $25.3M+42.9% | $17.7M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alkermes break its business down?
- Alkermes (ALKS) reports revenue by product across 4 parts — Aristada And Aristada Initio, LUMRYZ, LYBALVI and Vivitrol. Each is extracted from the segment footnotes and tracked over time.
- Where does Alkermes's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alkermes's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
